Biochemistry Department, Genetic Engineering and Biotechnology Research Division, National Research Centre, Dokki, Giza, Egypt.
High Throughput Molecular and Genetic laboratory, Center for Excellences for Advanced Sciences, National Research Centre, Dokki, Egypt.
Arch Physiol Biochem. 2022 Jun;128(3):569-575. doi: 10.1080/13813455.2019.1703004. Epub 2020 Jan 10.
Early diagnosis of breast cancer decreases mortality rate; therefore, novel diagnostic methods are urgently required. In this study, authors aimed to investigate the role of serum-derived miR-335 in breast cancer, and the expression of matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) and evaluating their feasibility and clinical utility as biomarkers for the early detection of breast cancer.
Blood samples were collected from a total of 210 individuals who were enrolled in this study. The participants were divided into newly diagnosed breast cancer patients ( = 115), patients with benign breast lesions ( =55) and healthy individuals as control group ( =40). The expression profile of miR-335, MMP2 and MMP9 were determined using quantitative polymerase chain reaction (qPCR).
MiR 335 expression level was down-regulated in primary breast cancer group as compared to benign breast group and healthy individuals with 98% and 94.9% sensitivity and specificity, respectively. MMP2 and MMP9 showed significantly higher expression levels in breast cancer group as compared to both benign and healthy group and reporting 92.7% and 93% sensitivity, respectively. The relations between investigated markers and pathologic types, staging, grading, and lymph node involvement were significant with these factors. Expression level of miR-335 was decreased with increased MMP2 and MMP9 at significant level.
MiR-335, MMP2, and MMP9 can be used as diagnostic markers in breast cancer.
早期诊断乳腺癌可降低死亡率；因此，迫切需要新的诊断方法。本研究旨在探讨血清来源的 miR-335 在乳腺癌中的作用，以及基质金属蛋白酶-2（MMP2）和基质金属蛋白酶-9（MMP9）的表达，并评估其作为乳腺癌早期检测生物标志物的可行性和临床实用性。
共采集了 210 名入组者的血液样本。将参与者分为初诊乳腺癌患者（n=115）、良性乳腺病变患者（n=55）和健康对照组（n=40）。采用实时定量聚合酶链反应（qPCR）检测 miR-335、MMP2 和 MMP9 的表达谱。
miR-335 在原发性乳腺癌组中的表达水平低于良性乳腺组和健康对照组，敏感性和特异性分别为 98%和 94.9%。MMP2 和 MMP9 在乳腺癌组中的表达水平明显高于良性组和健康对照组，敏感性分别为 92.7%和 93%。这些标志物与病理类型、分期、分级和淋巴结受累之间存在显著关系。miR-335 的表达水平随着 MMP2 和 MMP9 的升高而降低，差异具有统计学意义。
miR-335、MMP2 和 MMP9 可作为乳腺癌的诊断标志物。
